CFFO for the first quarter was $0.42 per diluted share, compared to $0.30 per diluted share for the same period in 2012, an increase of 40.0%. FFO per share, calculated in accordance with standards established by NAREIT, was $0.41 per diluted share, as compared to $0.30 per diluted share in the first quarter of 2012, an increase of 36.7%. AFFO for the quarter was $0.47 per diluted share, as compared to $0.30 per diluted share in the first quarter of 2012, an increase of 56.7%.
The company reported net income available to common stockholders for the quarter of approximately $8.4 million, or $0.05 per diluted share.
FFO, CFFO and AFFO are supplemental non-GAAP financial measures used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP net income available to common stockholders to FFO, CFFO and AFFO and definitions of terms are included at the end of this release.
Financing ActivityIn February 2013, the company raised net proceeds of approximately $287.0 million through the follow-on public offering of 14,605,000 shares of common stock.
In March 2013, the company completed the redemption of all 7,920,000 shares of its Series A preferred stock at $25.30217 per share, equal to the original issuance price of $25.00 per share, plus accrued and unpaid dividends up to the redemption date.
In April 2013, the company completed a follow-on public offering of 17,250,000 shares raising net proceeds of approximately $354.1 million. The company expects to use the net proceeds of the offering to fund a portion of the purchase p
|SOURCE BioMed Realty Trust, Inc.|
Copyright©2012 PR Newswire.
All rights reserved